North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations

Raed Alhusayen; Serena Dienes; Megan Lam; Afsaneh Alavi; Ali Alikhan; Maria Aleshin; Emad Bahashwan; Steve Daveluy; Noah Goldfarb; Amit Garg; Wayne Gulliver; Tarannum Jaleel; Alexa B. Kimball; Mark G. Kirchhof; Joslyn Kirby; Joi Lenczowski; Hadar Lev-Tov; Michelle A. Lowes; Irene Lara-Corrales; Robert Micheletti; Martin Okun; Lauren Orenstein; Susan Poelman; Vincent Piguet; Martina Porter; Barry Resnik; Cathryn Sibbald; Vivian Shi; Christopher Sayed; Se Mang Wong; Andrea Zaenglein; Helene Veillette; Jennifer L. Hsiao; Haley B. Naik

doi:10.1016/j.jaad.2024.11.071

North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations

Raed Alhusayen
, Serena Dienes
, Megan Lam
, Afsaneh Alavi
, Ali Alikhan
, Maria Aleshin
, Emad Bahashwan
, Steve Daveluy
, Noah Goldfarb
, Amit Garg
, Wayne Gulliver
, Tarannum Jaleel
, Alexa B. Kimball
, Mark G. Kirchhof
, Joslyn Kirby
, Joi Lenczowski
, Hadar Lev-Tov
, Michelle A. Lowes
, Irene Lara-Corrales
, Robert Micheletti

Martin Okun, Lauren Orenstein, Susan Poelman, Vincent Piguet, Martina Porter, Barry Resnik, Cathryn Sibbald, Vivian Shi, Christopher Sayed, Se Mang Wong, Andrea Zaenglein, Helene Veillette, Jennifer L. Hsiao, Haley B. Naik

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Background: Hidradenitis suppurativa (HS) affects different patient populations that require unique considerations in their management. However, no HS guidelines for these populations exist. Objective: To provide evidence-based consensus recommendations for patients with HS in 7 special patient populations: (i) pregnancy, (ii) breastfeeding, (iii) pediatrics, (iv) malignancy, (v) tuberculosis infection, (vi) hepatitis B or C infection, and (vii) HIV disease. Methods: Recommendations were developed using the Grading of Recommendations Assessment, Development, and Evaluation system to ascertain level of evidence and selected through a modified Delphi consensus process. Results: One hundred eighteen expert consensus statements are provided for the management of patients with HS across these 7 special patient populations.

Original language	English (US)
Pages (from-to)	825-852
Number of pages	28
Journal	Journal of the American Academy of Dermatology
Volume	92
Issue number	4
DOIs	https://doi.org/10.1016/j.jaad.2024.11.071
State	Published - Apr 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Dermatology

Access to Document

10.1016/j.jaad.2024.11.071

Cite this

Alhusayen, R., Dienes, S., Lam, M., Alavi, A., Alikhan, A., Aleshin, M., Bahashwan, E., Daveluy, S., Goldfarb, N., Garg, A., Gulliver, W., Jaleel, T., Kimball, A. B., Kirchhof, M. G., Kirby, J., Lenczowski, J., Lev-Tov, H., Lowes, M. A., Lara-Corrales, I., ... Naik, H. B. (2025). North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations. Journal of the American Academy of Dermatology, 92(4), 825-852. https://doi.org/10.1016/j.jaad.2024.11.071

@article{51e611c5f6914ba1b996a3bf540ffd7a,

title = "North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations",

abstract = "Background: Hidradenitis suppurativa (HS) affects different patient populations that require unique considerations in their management. However, no HS guidelines for these populations exist. Objective: To provide evidence-based consensus recommendations for patients with HS in 7 special patient populations: (i) pregnancy, (ii) breastfeeding, (iii) pediatrics, (iv) malignancy, (v) tuberculosis infection, (vi) hepatitis B or C infection, and (vii) HIV disease. Methods: Recommendations were developed using the Grading of Recommendations Assessment, Development, and Evaluation system to ascertain level of evidence and selected through a modified Delphi consensus process. Results: One hundred eighteen expert consensus statements are provided for the management of patients with HS across these 7 special patient populations.",

author = "Raed Alhusayen and Serena Dienes and Megan Lam and Afsaneh Alavi and Ali Alikhan and Maria Aleshin and Emad Bahashwan and Steve Daveluy and Noah Goldfarb and Amit Garg and Wayne Gulliver and Tarannum Jaleel and Kimball, \{Alexa B.\} and Kirchhof, \{Mark G.\} and Joslyn Kirby and Joi Lenczowski and Hadar Lev-Tov and Lowes, \{Michelle A.\} and Irene Lara-Corrales and Robert Micheletti and Martin Okun and Lauren Orenstein and Susan Poelman and Vincent Piguet and Martina Porter and Barry Resnik and Cathryn Sibbald and Vivian Shi and Christopher Sayed and Wong, \{Se Mang\} and Andrea Zaenglein and Helene Veillette and Hsiao, \{Jennifer L.\} and Naik, \{Haley B.\}",

note = "Publisher Copyright: {\textcopyright} 2025 American Academy of Dermatology, Inc.",

year = "2025",

month = apr,

doi = "10.1016/j.jaad.2024.11.071",

language = "English (US)",

volume = "92",

pages = "825--852",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Elsevier Inc.",

number = "4",

}

Alhusayen, R, Dienes, S, Lam, M, Alavi, A, Alikhan, A, Aleshin, M, Bahashwan, E, Daveluy, S, Goldfarb, N, Garg, A, Gulliver, W, Jaleel, T, Kimball, AB, Kirchhof, MG, Kirby, J, Lenczowski, J, Lev-Tov, H, Lowes, MA, Lara-Corrales, I, Micheletti, R, Okun, M, Orenstein, L, Poelman, S, Piguet, V, Porter, M, Resnik, B, Sibbald, C, Shi, V, Sayed, C, Wong, SM, Zaenglein, A, Veillette, H, Hsiao, JL & Naik, HB 2025, 'North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations', Journal of the American Academy of Dermatology, vol. 92, no. 4, pp. 825-852. https://doi.org/10.1016/j.jaad.2024.11.071

TY - JOUR

T1 - North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations

AU - Alhusayen, Raed

AU - Dienes, Serena

AU - Lam, Megan

AU - Alavi, Afsaneh

AU - Alikhan, Ali

AU - Aleshin, Maria

AU - Bahashwan, Emad

AU - Daveluy, Steve

AU - Goldfarb, Noah

AU - Garg, Amit

AU - Gulliver, Wayne

AU - Jaleel, Tarannum

AU - Kimball, Alexa B.

AU - Kirchhof, Mark G.

AU - Kirby, Joslyn

AU - Lenczowski, Joi

AU - Lev-Tov, Hadar

AU - Lowes, Michelle A.

AU - Lara-Corrales, Irene

AU - Micheletti, Robert

AU - Okun, Martin

AU - Orenstein, Lauren

AU - Poelman, Susan

AU - Piguet, Vincent

AU - Porter, Martina

AU - Resnik, Barry

AU - Sibbald, Cathryn

AU - Shi, Vivian

AU - Sayed, Christopher

AU - Wong, Se Mang

AU - Zaenglein, Andrea

AU - Veillette, Helene

AU - Hsiao, Jennifer L.

AU - Naik, Haley B.

PY - 2025/4

Y1 - 2025/4

N2 - Background: Hidradenitis suppurativa (HS) affects different patient populations that require unique considerations in their management. However, no HS guidelines for these populations exist. Objective: To provide evidence-based consensus recommendations for patients with HS in 7 special patient populations: (i) pregnancy, (ii) breastfeeding, (iii) pediatrics, (iv) malignancy, (v) tuberculosis infection, (vi) hepatitis B or C infection, and (vii) HIV disease. Methods: Recommendations were developed using the Grading of Recommendations Assessment, Development, and Evaluation system to ascertain level of evidence and selected through a modified Delphi consensus process. Results: One hundred eighteen expert consensus statements are provided for the management of patients with HS across these 7 special patient populations.

AB - Background: Hidradenitis suppurativa (HS) affects different patient populations that require unique considerations in their management. However, no HS guidelines for these populations exist. Objective: To provide evidence-based consensus recommendations for patients with HS in 7 special patient populations: (i) pregnancy, (ii) breastfeeding, (iii) pediatrics, (iv) malignancy, (v) tuberculosis infection, (vi) hepatitis B or C infection, and (vii) HIV disease. Methods: Recommendations were developed using the Grading of Recommendations Assessment, Development, and Evaluation system to ascertain level of evidence and selected through a modified Delphi consensus process. Results: One hundred eighteen expert consensus statements are provided for the management of patients with HS across these 7 special patient populations.

UR - https://www.scopus.com/pages/publications/85215584269

UR - https://www.scopus.com/pages/publications/85215584269#tab=citedBy

U2 - 10.1016/j.jaad.2024.11.071

DO - 10.1016/j.jaad.2024.11.071

M3 - Article

C2 - 39725212

AN - SCOPUS:85215584269

SN - 0190-9622

VL - 92

SP - 825

EP - 852

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 4

ER -

North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this